**Deaths from diabetes will rise: ISCR**

Source: [http://www.ptinews.com/news/7304890\_Deaths-from-diabetes-will-rise--ISCR.html 06 April 2016](http://www.ptinews.com/news/7304890_Deaths-from-diabetes-will-rise--ISCR.html%2006%20April%202016)

With an increase in life expectancy, obesity and sedentary lifestyles, the prevalence of diabetes will rise dramatically and also the number of resulting deaths, a research body today warned and stressed for greater investments in research to find its "affordable" treatment.

Noting that in 2012 there were an estimated 2.2 lakh diabetes related deaths in India, Indian Society of Clinical Research (ISCR) said that there is an urgent need to focus on prevention, early detection and treatment of diabetes to effectively combat the chronic disease.

Recognising the growing prevalence of diabetes particularly in low and middle income countries and its increasing burden on society and the healthcare delivery system, 'Beat Diabetes' is the theme adopted by the WHO for World Health Day which falls on April 7.

"Diabetes is an enormous public health challenge in India and cuts across all economic strata. We need greater investments in clinical research to find more affordable and accessible treatment options for the increasing number of diabetics in our country. This will reduce the pressure on our overburdened health infrastructure," said Suneela Thatte, President, ISCR.

It is estimated that by 2030, there will be more than 100 million patients living with diabetes in India, while according to WHO's Diabetes Country Profiles, in 2012 there were an estimated 2.2 lakh diabetes related deaths in India.

With an increase in life expectancy, obesity and sedentary lifestyles, the prevalence of diabetes will rise dramatically and so will the corresponding number of deaths from diabetes, the body said.

ISCR said that it is optimistic that the recent changes by the regulatory authorities in India to create a balanced and scientific environment for the conduct of clinical research in the country will see sponsors increase investments in endemic illnesses in the region like diabetes.

PHARMA INDUSTRY OVERVIEW

Globally, India ranks 3rd in terms of volume and 14th in terms of value.According to Department of Pharmaceuticals, [Ministry of Chemicals and Fertilizers](https://en.wikipedia.org/wiki/Ministry_of_Chemicals_and_Fertilizers_(India)), the total turnover of India's pharmaceuticals industry between 2008 and September 2009 was US$21.04 billion. [Hyderabad](https://en.wikipedia.org/wiki/Hyderabad), [Mumbai](https://en.wikipedia.org/wiki/Mumbai), [Bangalore](https://en.wikipedia.org/wiki/Bangalore) and [Ahmedabad](https://en.wikipedia.org/wiki/Ahmedabad) are the major pharmaceutical hubs of India. While the domestic market is worth US$13.8 billion as of 2013, and is expected to reach US$49 billion by 2020

The [government](https://en.wikipedia.org/wiki/Government_of_India) started to encourage the growth of drug manufacturing by Indian companies in the early 1960s, and with the Patents Act in 1970.[[4]](https://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India#cite_note-4) However, economic liberalization in 90s by the former Prime Minister [P.V. Narasimha Rao](https://en.wikipedia.org/wiki/P.V._Narasimha_Rao) and the then [Finance](https://en.wikipedia.org/wiki/Finance) [Minister](https://en.wikipedia.org/wiki/Minister_(government)), [Dr. Manmohan Singh](https://en.wikipedia.org/wiki/Dr._Manmohan_Singh) enabled the industry to become what it is today. This patent act removed composition [patents](https://en.wikipedia.org/wiki/Patent) from food and drugs, and though it kept process patents, these were shortened to a period of five to seven years.

The lack of patent protection made the Indian market undesirable to the multinational companies that had dominated the market

The number of purely Indian pharma companies is fairly low. Indian pharma industry is mainly operated as well as controlled by dominant foreign companies having subsidiaries in India due to availability of cheap labor in India at lowest cost

**Top 10 Listed pharmaceutical companies in India by Market Capitalization as of July 2015**

|  |  |  |
| --- | --- | --- |
| **Rank** | **Company** | **Market Capitalization 2015 (INR crores)** |
| 1 | [Sun Pharmaceutical](https://en.wikipedia.org/wiki/Sun_Pharmaceutical) | 2,17,636 |
| 2 | [Lupin Ltd](https://en.wikipedia.org/wiki/Lupin_Ltd) | 84,193 |
| 3 | [Dr. Reddy's Laboratories](https://en.wikipedia.org/wiki/Dr._Reddy%27s_Laboratories) | 63,779 |
| 4 | [Cipla](https://en.wikipedia.org/wiki/Cipla) | 52,081 |
| 5 | [Aurobindo Pharma](https://en.wikipedia.org/wiki/Aurobindo_Pharma) | 42,454 |
| 6 | [Cadila Healthcare](https://en.wikipedia.org/wiki/Cadila_Healthcare) | 38,677 |
| 7 | [Glenmark Pharmaceuticals](https://en.wikipedia.org/wiki/Glenmark_Pharmaceuticals) | 29,047 |
| 8 | [GlaxoSmithKline Pharmaceuticals Ltd](https://en.wikipedia.org/wiki/GlaxoSmithKline_Pharmaceuticals_Ltd) | 28,587 |
| 9 | Divis Laboratories | 24,847 |
| 10 | [Torrent Pharmaceuticals](https://en.wikipedia.org/wiki/Torrent_Pharmaceuticals) | 22,320 |

|  |  |  |  |
| --- | --- | --- | --- |
|  | |  |  | | --- | --- | |  | [ETHealthWorld.com](http://health.economictimes.indiatimes.com/news/pharma/indian-drug-firms-to-face-challenges-in-us-market-icra/51692569) |   [Indian **pharma industry** to face hurdles in US along with currency headwinds in EMs](http://www.indiainfoline.com/article/news-top-story/indian-pharma-industry-to-face-hurdles-in-us-along-with-currency-headwinds-in-ems-116040400339_1.html) |

Indian pharma industry to face hurdles in US along with currency headwinds in EMs **According to Subrata Ray, Sr** **Group Vice President for Corporate Ratings at ICRA, “Increased regulatory scrutiny as reflected in growing issuance of warning letters/import alerts and consolidation of supply chain in US market resulting in pricing pressures will have an impact on competitiveness of Indian pharmaceutical companies.”**

[Sun **Pharma** to tap Japan's growing focus on generics](http://www.business-standard.com/article/companies/sun-pharma-to-tap-japan-s-growing-focus-on-generics-116033000922_1.html)

<http://www.business-standard.com/article/companies/sun-pharma-to-tap-japan-s-growing-focus-on-generics-116033000922_1.html>



Sun Pharmaceuticals is expected to gain from a growing focus on generic drugs in Japan.

India’s largest drugmaker by sales announced a deal to acquire Novartis’ branded drug portfolio in Japan for $293 million (Rs 1,900 crore) on Tuesday.

The drugs have a combined revenue of $160 million (about Rs 1,000 crore), less than five per cent of Sun Pharma’s consolidated annual sales of over Rs 27,000 crore. About half of Sun Pharma’s revenue comes from the US, but sales in that country have declined over the last few quarters because of regulatory issues at its plants

[**Role of social media in pharma industry**](http://www.financialexpress.com/article/pharma/cover-story/role-of-social-media-in-pharma-industry/231319/)

**The Indian pharmaceutical industry is one of the largest and steadily growing industries. Inspite of this growth, the method of traditional pharma marketing has not changed much. It has always focused on promoting their brands and products to the doctor, who is the centre-piece of this industry, through their medical representatives. All marketing efforts including communication channels, strategies, CRMs, policies etc are devised keeping the doctor in mind.**

**Influence of technology on marketing**

**With the advent of globalisation in the 90’s, the ball of digital revolution set rolling with the Internet boom followed by the entry of mobile phones in the late 90’s. With a population of 1.20 billion people today, India boasts of over 900 million mobile phones in the country. Smart phones are fast replacing standard mobile phones and every single service provider is offering deals on mobile Internet connectivity with their 3G and 4G offerings. Consumers are thus increasingly exposed to a gigantic pool of information at their fingertips. Social platforms like Facebook,**[**WhatsApp**](http://www.financialexpress.com/tag/whatsapp/)**, Twitter, Instagram, YouTube etc are playing an important role in how information is consumed. Therefore, it is extremely difficult for any industry to overlook social media as a means of communication with their consumers.**

[**SMS Pharmaceuticals acquires stake in Lifesciences India**](http://www.indiainfoline.com/article/news-top-story/sms-pharmaceuticals-acquires-stake-in-lifesciences-india-116040300046_1.html)

**SMS Pharmaceuticals Limited has announced that the Company had made SMS Lifesciences India Private Limited its wholly owned subsidiary by acquiring it's 100% Equity Shares (i.e. Rs. 1,00,000/- paid up share capital) as on April 01, 2016.**

**SMS Pharmaceuticals Ltd ended at Rs. 85.05, up by Rs. 1.65 or 1.98% from its previous closing of Rs. 83.4 on the BSE.**

**The scrip opened at Rs. 83.95 and touched a high and low of Rs. 86.95 and Rs. 83.95 respectively. A total of 49485(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 719.97 crore.**

**The BSE group 'B' stock of face value Rs. 1 touched a 52 week high of Rs. 137.5 on 28-Dec-2015 and a 52 week low of Rs. 50.1 on 28-Apr-2015. Last one week high and low of the scrip stood at Rs. 91.75 and Rs. 78.05 respectively.**

**The promoters holding in the company stood at 63.88 % while Institutions and Non-Institutions held 0.53 % and 35.59 % respectively.**

**The stock traded below its 100 DMA.**

[**Pharma sales growth tumble in March over govt drug ban, price control**](http://www.ibtimes.co.in/pharma-sales-tumble-march-over-govt-drug-ban-price-control-674355)

**The Indian pharma sector has registered the slowest monthly sales growth in March for financial year 2015-2016, primarily hit by the government's recent decisions to ban 344 combination drugs and bring nearly 800 essential medicines under price control, as noted by market research firm AIOCD Pharmasofttech AWACS in a report.**

**The health ministry March 10** [**banned**](http://www.ibtimes.co.in/indian-pharma-sector-witness-rs-1000-crore-loss-due-drug-ban-670895) **certain combination drugs, notifying that these combination drugs were found to be risking the lives of humans and hence were subsequently banned under the Drugs and Cosmetics Act, 1940. Later, the National Pharmaceutical Pricing Authority (NPPA) brought essential medicines under the ambit of**[**price control**](http://www.ibtimes.co.in/govt-brings-800-drug-formulations-under-price-control-670620)**.**

**Pharma companies have challenged the government's decision in the Delhi High Court. The court ordered a stay on the ban and the next hearing is scheduled for April 18.**

**AIOCD AWACS estimated that the ban could result in the loss of Rs. 3,049 crore to the Indian pharma industry annually. Pharma industry registers lowest growth in March**

[**India's BDR Pharma, Lee Pharma end battle to copy drugs amid patent debate**](http://www.livemint.com/Companies/lj7DTEiBp6Feg8Qc4yjITO/Indias-BDR-Pharma-Lee-Pharma-end-battle-to-copy-drugs-amid.html)



**Mumbai: Two Indian drugmakers said they had given up a battle to copy drugs developed by Bristol Myers Squibb and AstraZeneca, blaming a lack of government support for cheap generics and pressure from Big Pharma.Both companies, BDR Pharma and Lee Pharma, had been seeking so-called compulsory licenses that override patents and allow generics firms in India to launch cheap copies of medicines manufactured by big Western drugmakers.**

[**Despite ban on drugs, pharma sector to report good growth for 4th quarter of 2015-16**](http://www.dnaindia.com/money/report-despite-ban-on-drugs-pharma-sector-to-report-good-growth-for-4th-quarter-of-2015-16-2201369)

**The pharma sector is expected to report good growth for the fourth quarter of 2015-16 despite regulatory concerns raised by USFDA and the recent ban on 344 fixed dose combinations imposed by the government, as per a report.**

**"We expect the pharma sector to report good growth for Q4FY16 despite regulatory issues from USFDA and the recent ban on 344 FDC. The price increase, volume growth and new product introduction are likely to drive the domestic pharma market," Centrum Broking said in its recent report here.**

**12 april 2016** [**Pharma sales growth tumble in March over govt drug ban, price control**](http://www.ibtimes.co.in/pharma-sales-tumble-march-over-govt-drug-ban-price-control-674355)

**The Indian pharma sector has registered the slowest monthly sales growth in March for financial year 2015-2016, primarily hit by the government's recent decisions to ban 344 combination drugs and bring nearly 800 essential medicines under price control, as noted by market research firm AIOCD Pharmasofttech AWACS in a report.**

**The health ministry March 10** [**banned**](http://www.ibtimes.co.in/indian-pharma-sector-witness-rs-1000-crore-loss-due-drug-ban-670895) **certain combination drugs, notifying that these combination drugs were found to be risking the lives of humans and hence were subsequently banned under the Drugs and Cosmetics Act, 1940. Later, the National Pharmaceutical Pricing Authority (NPPA) brought essential medicines under the ambit of**[**price control**](http://www.ibtimes.co.in/govt-brings-800-drug-formulations-under-price-control-670620)**.**

**Pharma industry registers lowest growth in March**

**The pharma industry grew by 6.4 percent in March 2016, the slowest growth for this fiscal. The last lowest growth was 9.3 percent in November 2015, the market research firm said.**



**15 April 2016** [**Pharmaceutical Industry And Self-Regulation**](http://www.legalera.in/legal-articles/item/18984-pharmaceutical-industry-and-self-regulation.html)

### ***The amended MCI regulations for doctors coupled with notified DOP Code for the entire pharmaceutical industry should make financial transactional relationship between physicians and the pharmaceutical industry in India clean and transparent* - Vineet Chaudhary**

The Indian pharmaceutical industry has been witnessing remarkable growth over the past few years. It currently tops the charts amongst India's science-based industries with large ranging capabilities in the complex field of drug manufacture and technology. A highly organised sector, the Indian pharmaceutical industry is estimated to be worth $4.5 billion, growing at about 8 to 9 percent annually.

India is now among the five pharmaceutical emerging markets. There will be new drug launches, new drug filings, and Phase II clinic trials which are expected in the upcoming years. The domestic pharmaceutical market is expected to register a strong double-digit growth of 13-14 per cent in the coming times. Due to rapid growth of the pharmaceutical industry, marketing has also become an important determinant of the survival and growth of various pharmaceutical companies, amidst increasing competition faced by them.

In the present article, we enlist the key features and efficacy of statutes and various codes regulating the Indian Pharmaceuticals Marketing Practices

**Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954**

Advertisements of drugs and pharmaceuticals should ideally be strictly regulated and the legislation should not allow advertisement of prescription medicines in any form in any kind of media. However, apart from restraint on advertising of prescription drugs, and making claims to provide prevention or cures of certain diseases under the Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954, there are as such no legal constraints on advertising. The Act basically prohibits advertisements about diagnosis, cure, mitigation or prevention of 54 diseases and listed disorders such as cancer, diabetes, epilepsy, leucoderma, paralysis, sexual impotence etc. However, as a matter of fact, in the present scenario, the law is somewhat out modelled and outdated. While it prohibits misleading health claims in the print media, it has no provision to tackle the advertisements that may appear on television or internet. The billboards in Delhi, the local train railway compartments in Mumbai, advertisement pages of newspapers and now, electronic media are in constant breach of the Act. As such, there is an immediate need not only to formulate a strict law but also for strict vigil on the various claims made by unscrupulous practitioners about their claims for curing different ailments and punish defaulters accordingly

15 April 2016 [Advent, Baxter preparing bids for **India's** Gland **Pharma** - sources](http://www.business-standard.com/article/reuters/advent-baxter-preparing-bids-for-india-s-gland-pharma-sources-116041500681_1.html)

[HONG KONG](http://www.business-standard.com/search?type=news&q=Hong+Kong) (Reuters) - Global buyout firm Advent International and U.S.-based Baxter International are among suitors preparing to submit separate bids to buy unlisted Indian drugmaker [Gland](http://www.business-standard.com/search?type=news&q=Gland) Pharma Ltd, three people with direct knowledge of the matter told Reuters.

[A](http://www.business-standard.com/search?type=news&q=A) deal would underscore the positive outlook for drugmakers in India, which is a major supplier to the world and counts the United States as its largest export market thanks to lower manufacturing and labour costs.

Indian drugmakers are among the world's biggest producers of cheap generic medicines, as developed nations battle rising healthcare costs and big-selling drugs going off-patent in the lucrative U.S. market.

Overseas drugmakers as well as private equity firms such as KKR & Co and Singapore's state investment firm Temasek Holdings have invested in the Indian companies in the recent past to cash in on growing demand for cheaper drugs overseas.

Gland Pharma founders and KKR, who jointly own about 96 percentof the company, are selling their combined stake, which is valued at between $1 billion and $1.5 billion, the people said.

Indian drugmaker Torrent Pharmaceuticals is the other company set to place binding bids due by middle of next month, said the people, who declined to be identified as the deal talks are confidential.

Advent, KKR and Baxter declined to comment. Officials at Gland and Torrent did not respond to Reuters' request for comment.

KKR invested about $200 million in Gland Pharma in 2013, at that time the largest private equity investment in the local pharmaceutical sector. The stake size was not disclosed, but sources said the company was valued at about $600 million then.

Gland Pharma, based in the southern [India](http://www.business-standard.com/search?type=news&q=India) city of Hyderabad, makes injectables - widely-used medicines administered through vials, syringes, bags and pumps, which are harder to manufacture than regular medicines.

A shortage of such injectables in recent years has driven up prices and made it an increasingly lucrative business opportunity for drugmakers, sparking investors' interest in companies such as Gland Pharma.

Drugs giant Pfizer acquired U.S. firm Hospira for $17 billion last year partly to bolster its injectable drugs business.

Mylan NV paid $1.6 billion to buy the injectable drugs unit of India's Strides Arcolabs - now known as Strides Shasun - in 2013.

|  |
| --- |
| **12 April 2016** [**Pharma** may report good growth for Q4 of last fiscal](http://indiatoday.intoday.in/story/pharma-may-report-good-growth-for-q4-of-last-fiscal-report/1/641177.html)  Mumbai, Apr 12 (PTI) The pharma sector is expected to report good growth for the fourth quarter of 2015-16 despite regulatory concerns raised by USFDA and the recent ban on 344 fixed dose combinations imposed by the government, as per a report.  "We expect the pharma sector to report good growth for Q4FY16 despite regulatory issues from USFDA and the recent ban on 344 FDC. The price increase, volume growth and new product introduction are likely to drive the domestic pharma market," Centrum Broking said in its recent report here.  "For Q4FY16, we expect our pharma universe to report 14 per cent year-on-year growth in revenues, 52 per cent in EBIDTA and 31 per cent in net profit. We expect 570 bps year-on-year improvement in margin to 23.2 per cent from 17.5 per cent mainly due to the reduction in material cost.  "We expect EBIDTA margin to improve by 570bps year-on-year to 23.2 per cent from 17.5 per cent due to price revision, volume growth and softening of raw material prices and pharma companies to benefit from the reduction in material cost, led by decline in prices of crude-based chemicals and solvents," it said.  Moreover, the companies are likely to benefit from the reduction in transportation cost due to lower fuel prices, it added.  According to the report, the sector is passing through uncertainty on the regulatory front, price decline in NLEM products and ban on 344 FDC drugs.  However, over 60 companies have moved the Delhi High Court and got a stay against the ban.  As per the report, it expects pharma MNCs in the country to perform well in future due to reduction in material cost, line extension of existing brands and their debt-free status.  However, the report pointed out that the slowdown in the domestic market and regulatory risks for manufacturing facilities are key issues for the industry. PTI AP NRB ABM |

17 April 2016 [Indian **pharmaceutical** team to attend Cairo meet](http://www.business-standard.com/article/news-ians/indian-pharmaceutical-team-to-attend-cairo-meet-116041700374_1.html)

A 44-member delegation from [India](http://www.business-standard.com/search?type=news&q=India) will participate in an international pharma exhibition 'Pharmaconex 2016' in Cairo from April 19 to 21.

The delegation's participation at the international pharma convention will be led by the Pharmaceutical Export Promotion Council of India or Pharmexcil, an official statement said.

The delegation will include prominent Indian manufacturers and exporters of pharmaceuticals, nutraceuticals, dietary supplements, pharmaceutical formulation intermediates, active pharmaceutical ingredients, hospital supplies, herbal medicines, cosmetics, excipients, fine chemicals and a wide range of innovative high quality pharma products.

India is the largest provider of generic drugs globally, with the Indian generics accounting for 20 percent of the global exports by volume, according to the statement.

The Indian pharma industry, expected to grow over 15 percent per annum between 2015 and 2020, will outperform the global pharma industry.

At present, the market size of the pharmaceutical industry in India stands at $20 billion.

As of March 2014, Indian pharmaceutical manufacturing facilities registered with the US Food and Drug Administration stood at 523, the highest for any country outside the US.

India is expected to be the third largest global market for active pharmaceutical ingredients by 2016, with a 7.2 percent increase in market share.

Indian generic formulations enjoy a good reputation worldwide for quality and cost effectiveness and are exported to more than 200 countries, including the US, European Union and Japan.

India's pharma exports touched 20 billion dollars in 2015 and are expected to reach 27 billion dollars by 2016.

The governments and the business communities in India and Egypt are working closely to promote the dynamism in bilateral economic relations.

The visit of the pharma delegation is part of the efforts to boost trade relations between the two countries.

17 April 2016 [CPI (M) seeks safety audit of chemical units in North Andhra](http://www.thehindu.com/news/cities/Visakhapatnam/cpi-m-seeks-safety-audit-of-chemical-units-in-north-andhra/article8485629.ece)

CPI (M) State Secretariat member Ch. Narsinga Rao and district secretary K. Loknadham on Saturday demanded safety audit of all chemical units in north Andhra and a criminal case registered against Divi’s Laboratories Ltd at Uppada near Bheemunipatnam for the death of three workers following a blast on April 6.

Addressing a press conference here, they said even after so many days of the fatal accident, HRD Minister Ganta Srinivasa Rao, who represents Bheemli constituency, had not visited the accident-hit factory.

Stating that accidents were occurring at regular intervals at various pharma and other chemical units in North Andhra, they said a safety audit was required immediately as the future of over 45,000 workers employed by various pharma units was at stake.

Mr. Rao said the Divi’s unit should shutdown its operations till the safety audit was conducted by independent experts. He said as of now three had succumbed to burns after April 6 accident and two more were undergoing treatment at a private hospital with severe burns.

The CPI (M) leader said not only there was failure by the statutory agencies to ensure adherence to safety precautions at Jawaharlal Nehru Pharma City, Parawada, Hetero Drugs, Nakkapalli, Deccan Chemicals, near Payakaraopeta and other areas but also the implementation of welfare measures for the workforce was a big casualty at various chemical units.

**Dosage forms** (also called **unit doses**) are essentially [pharmaceutical drug](https://en.wikipedia.org/wiki/Pharmaceutical_drug) products in the form in which they are marketed for use, typically involving a mixture of active drug components and nondrug components (excipients), along with other non-reusable material that may not be considered either ingredient or packaging (such as a capsule shell, for example). The term **unit dose** can also sometimes encompass non-reusable *packaging* as well (especially when each drug product is individually packaged[[1]](https://en.wikipedia.org/wiki/Dosage_form#cite_note-1)), although the FDA distinguishes that by *unit-dose "packaging" or "dispensing"*.[[2]](https://en.wikipedia.org/wiki/Dosage_form#cite_note-2) Depending on the context, *multi(ple) unit dose* can refer to distinct drug products *packaged* together, or to a *single* drug product containing multiple drugs and/or doses. The term **dosage form** can also sometimes refer *only*to the [pharmaceutical formulation](https://en.wikipedia.org/wiki/Pharmaceutical_formulation) of a drug product's constituent drug substance(s) and any blends involved, without considering matters beyond that (like how it is ultimately configured as a consumable product such as a capsule, patch, etc.). Because of the somewhat vague boundaries and unclear overlap of these terms and certain variants and qualifiers thereof within the pharmaceutical industry, caution is often advisable when conversing with someone who may be unfamiliar with another person's use of the term



DRUG DISCOVERY

31 March 2016 [Stem Cell Research Startup Transcell Biologics Gets Backed By Indian Angel Network](http://thetechportal.in/2016/03/31/stem-cell-research-startup-transcell-biologics-gets-funding-indian-angel-network/)

Transcell Biologics, a biotech startup based in Hyderabad, has announced that it has raised an undisclosed amount of funding from Indian Angel Network (IAN) in its seed funding round.

This funding round was led by Sanjay Jesrani and Nagendra Bandaru on behalf of IAN. As a part of the funding deal, they will also join the board of the company. The amount raised in this round, will be used by the company for productization of the stem cell based platforms in both the therapeutic and non-therapeutic areas.

Founded in 2009 by Subhadra Dravida, Transcell Biologics is a biotech enterprise that aims to develop innovative and transformative stem cell-based approaches in advancing evidence based practice in disease management.

The Company has started creating the wealth of unique repository of India specific patient derived tissues/samples for the purpose of research and development towards advancements in modern adult stem cell technology based drug discovery in Oncology & Brain diseases.

It has also initiated the pre-clinical milestones in Regenerative Medicine addressing Rheumatoid Arthritis, Muscular Dystrophies (Orphan disease), Stroke & Periodontal diseases.

It gets insights from it’s innovative capabilities in donor and patient derived stem cell repository creation, integrating the regenerative medicine and drug discovery applications of the cell based platforms.

Using those insights, the company has created a cohesive research and development inspired ecosystem that creates stem cell repository, develops cell based platforms for both therapeutic and non-therapeutic applications, facilitates advanced regenerative medicine tools to treat debilitating diseases of the mankind and delivers novel, patient-based, screening methods to discover druggable molecules.

Subhadra Dravida, founder and CEO of the company, said,

**Transcell Biologics provides end-to-end solution offerings in Stem cell Bio banking & ensures quality processing & presentations for the intended applications. We are built on the rock bed of home grown technologies with intellectual property as our business asset. We value the support and guidance from IAN, positioning ourselves and continue to strive to give back to the communities by translating advanced scientific technologies reaching clinics.**

Commenting on the investment, Sanjay Jesrani said,

**Last few years we have seen Stem cell banks becoming quite popular in India. With the advancement in technology, newer players are entering the market with an aim to preserve precious lives of the coming generation. Transcell Biologics is one such company who wants to help the needy with the support of their home grown technologies.**

According to the research from Axis Research, it pegs the growth of this global market to $67 billion in 2017 by expanding the definition and scope of the stem cell applications in Regenerative Medicine and drug discovery.

2 April 2016 [All **drugs** from nature only : GVKBIO](http://news.webindia123.com/news/Articles/India/20160402/2829391.html)

Hyderabad-based GVKBIO Director Dr Raveendra Dayam today opined that "Natural products have been the single most productive source of leads for the development of drugs.

Many new products are in clinical development, particularly as anti-cancer agents and anti-infectives" Dr. Raveendra said while addressing at the inauguration session of one-day national workshop on 'Modern Trends in Drug Discovery and Development' held at GITAM University here,

"Medicine is essential for life. It came from nature only. Identification of medicine is very expensive. It is a basic need to get treatment" he reasoned.

Expressing displeasure about the pharmacy industry, which is focusing where it get benefited, he appealed to the academic researchers to focus on diseases which are neglected by the industry, like Malaria, Dengue fever.

Dr. Raveendra enlightened about the computer based drug discovery process and in silico drug discovery trends in industry. Earlier, Sanjay, Principal, School of Technology (SoT), GITAM University has presided over the inaugural session and made the opening remarks. Dr. Rambabu Gundala, Convenor & Head, Department of Chemistry, delivered the welcome speech and explained the objectives of the workshop. UNI KNR KVV AK 1725

4 April 2016 [Workshop on **drug discovery**](http://www.thehindu.com/todays-paper/tp-features/tp-educationplus/workshop-on-drug-discovery/article8430173.ece)

“Natural products have been the single most productive source of leads for the development of drugs. Many new products are in clinical development, particularly as anti-cancer agents and anti-infections” Dr. Raveendra Dayam, Director, GVKBIO, Hyderabad opined.

He was speaking at the national workshop on ‘Modern Trends in Drug Discovery and Development’ in GITAM University. He expressed his displeasure about the pharmacy industry, which is focusing only the areas where it gets benefitted and appealed to the researchers to focus on diseases which are neglected like malaria and dengue.

6 April 2016 [**Medical** University, Daiichi Sankyo & Mitsubishi UFJ Capital to open innovation research to **...**](http://www.pharmabiz.com/NewsDetails.aspx?aid=94424&sid=2)